INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS
lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French |
Published |
09.03.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
L'invention concerne des composés indazole-3-carboxamides pour le traitement de diverses maladies et pathologies. Plus particulièrement, la présente invention concerne l'utilisation d'un composé indazole-3-carboxamide ou d'analogues de celui-ci, dans le traitement de troubles caractérisés par l'activation de la signalisation de la voie Wnt (par exemple un cancer, une prolifération cellulaire anormale, l'angiogenèse et l'arthrose), la modulation d'événements cellulaires à médiation par la signalisation de la voie Wnt, ainsi que des maladies génétiques et des états/troubles/maladies neurologiques dus à des mutations ou à une dérégulation de la voie Wnt et/ou d'un ou de plusieurs composants de la signalisation par Wnt. L'invention concerne également des méthodes de traitement d'états pathologiques associés à Wnt. |
---|---|
Bibliography: | Application Number: CA20122848659 |